INTRODUCTION
============

Global dissemination of multiple antibiotic resistance and virulence traits by plasmids poses an increasing threat to the successful treatment of bacterial infectious diseases in animals and humans alike ([@B4]). Extended-spectrum β-lactamase (ESBL) producing *Escherichia coli* has become one of the most important causes of nosocomial and community acquired infections ([@B11]; [@B15]) and most of the ESBL enzymes recognized are expressed from genes mapped to plasmids ([@B32]; [@B16]). It is acknowledged that the horizontal transfer of plasmids carrying these ESBL genes is an important contributory factor in the epidemiology of this bacterial ecosystem ([@B13]). The predominant ESBL families of clinical importance include TEM, SHV, and CTX-M ([@B5]); and the genes conferring this resistance phenotype in animals include *bla*~CTX-M-1~ (the most frequently identified ESBL), *bla*~CTX-M-14~, *bla*~TEM-52~, and *bla*~SHV-12~ ([@B13]). *E. coli* is the most common bacterial species identified with these genes.

Plasmids evolve as an integral part of the bacterial genome, consisting of several extra-chromosomal traits, one of which is their resistance genes, which can be exchanged among bacteria of different origins by conjugation ([@B7]). Those expressing an ESBL phenotype frequently carry genes encoding resistance to other commonly used antimicrobial drug classes (such as aminoglycosides, chloramphenicols, fluoroquinolones, or tetracycline; [@B19]; [@B35]). Plasmid-mediated transfer of drug-resistance genes among various bacterial species is considered to be one of the most important mechanisms driving the spread of multi-drug resistance (MDR) markers. The use of antimicrobial compounds in human and veterinary medicine also constitutes a risk factor for the selection and dissemination of resistant clones, and also plasmids containing the corresponding resistance genes. Consequently, these features limit the treatment options available when ESBL-producing organisms are encountered. Therefore, as a first step to address this problem, it is important to monitor the dissemination of ESBL-producing bacteria, characterizing these microbes when they arise. Moreover, studies describing the genetic basis of plasmids derived from bacteria recovered from animals, humans, and the environment are essential.

Extended-spectrum-β-lactamase transmission is mainly driven by insertion sequences, transposons, integrons, and plasmids, some of which are homologous in isolates from both food producing animals and humans ([@B43]; [@B40]). Plasmid-encoded genes can arise from multiple sources ([@B3]) being subsequently disseminated by horizontal gene transfer (HGT). HGT is responsible for the dissemination of many traits associated with bacteria, including antibiotic resistance and virulence. In addition, broad-host-range plasmids play an important role in bacterial adaptation to new environments. Taken together these characteristics provide much of the motivation of extending our understanding of the structural relationships that exist between plasmids from a variety of bacterial sources. Following the dissemination routes of antibiotic resistance genes on ESBL-harboring plasmids is important to broaden our knowledge of how these genes are shared horizontally across species boundaries as well as their evolution ([@B46]). Moreover, characterization based on plasmid profiling and the definition of corresponding incompatibility (Inc) group is an integral part of plasmid epidemiological surveillance enhancing discrimination between *E. coli* strains ([@B8]).

In this paper, we report on the preliminary characterization of ESBL-producing *E. coli* isolates that were originally described following culture and phenotypic studies in healthy humans and animals in Switzerland. The aims of this study were (i) to identify the plasmids relating to ESBL markers, (ii) to characterize the donor *E. coli* isolates by phylogenetic grouping and multi-locus sequence typing (MLST), and (iii) to determine the replicon types and S1 nuclease-based plasmid profiles, following pulsed-field gel electrophoresis (PFGE). The epidemiological data presented extends our understanding of this resistance type in humans and animals.

MATERIALS AND METHODS {#s1}
=====================

BACTERIAL STUDY STRAINS COLLECTIONS
-----------------------------------

Extended-spectrum-β-lactamase-producing *E. coli* (*n* = 87) were cultured from fecal samples of healthy humans (*n* = 34) and healthy food-producing animals (*n* = 52) in Switzerland, as well as one from a mastitis milk sample. To prevent sample clustering, at most two animal samples per farm were taken throughout Switzerland. All human samples were collected in urban areas, and each individual was tested only once. Prior to testing, all isolates were streaked for purity on MacConkey agar (Oxoid, Basingstoke, England). The protocols for collecting and isolating the strains were described previously ([@B17], [@B18]).

PLASMID PROFILING
-----------------

Plasmid DNAs from all isolates were purified using the WizardR Plus SV DNA Purification System (Promega, Madison, WI, USA) according to the manufacturer's instructions, followed by separation in a 0.8% (w/v) agarose gel (SeaKemR LE Agarose, Lonza Wokingham Ltd, UK) staining with GelRed^TM^ (Biotium, Hayward, CA, USA). S1-nuclease (Promega, Madison, WI, USA) digestion as well as PFGE analysis were performed for selected 32 isolates based on their small plasmid subgroups and corresponding ESBL genotypes reported previously (the complete isolate information is listed in **Figure [A1](#F1){ref-type="fig"}** in Appendix). Briefly, the procedure included a lysis step of the bacterial cells embedded in agarose plugs followed by digestion with 8 U S1 nuclease at 37°C for 45 min. Finally, each plasmid sample was resolved by PFGE in a Chef-Mapper^®^ XA System (Bio-Rad, USA) at 14°C, with a switch time between 1 and 12 s, at 6 V/cm on a 120° angle in 0.5× TBE buffer for 18 h. Each DNA band was considered a unit length of linear plasmid ([@B1]). The approximate molecular mass of plasmids was determined by comparing with *E. coli* 39R 861, containing four reference plasmids, of known molecular weights 6.9-, 36-, 63-, and 147-kb ([@B26]).

PCR-BASED REPLICON TYPING
-------------------------

Plasmids were assigned to incompatibility groups on the basis of the presence of specific replicon sequences identified by PCR using the primers previously designed and the corresponding amplification protocols described ([@B8]).

CONJUGATION-BASED MATING EXPERIMENTS AND VERIFICATION
-----------------------------------------------------

Thirty-two selected isolates were analyzed individually, for their ability to transfer cefotaxime resistance to a rifampicin-resistant, plasmid-free *E. coli* recipient (26R 793). Conjugation experiments were carried out using a broth mating protocol. Transconjugants were selected on Luria-Bertani (LB) agar plates (Difco Laboratories, Becton Dickinson, Sparks, MD, USA) containing 4 μg/ml cefotaxime (Thermo Fisher Scientific Inc., USA) and 100 μg/ml rifampicin (Sigma, Dublin, Ireland). Transfer frequencies were calculated per donor cell. Susceptibility tests were performed to confirm the plasmid transfer as described below, followed by S1-nuclease PFGE and PCR-based replicon typing (PBRT) to test which plasmids and resistance markers were transferred.

ANTIMICROBIAL SUSCEPTIBILITY TESTING
------------------------------------

Donor strains and the corresponding transconjugants were tested for their susceptibility to a panel of antimicrobial compounds by disk diffusion, following recommendations of the Clinical and Laboratory Standards Institute (CLSI). Susceptibility/resistance was interpreted according to the CLSI document M100-S21([@B10]). The panel of antibiotic-containing disks (Becton, Dickinson, USA) along with their abbreviated names consisted of ampicillin (AM), amoxicillin--clavulanic acid (AMC), chloramphenicol (C), ciprofloxacin (CIP), cefpodoxime (CPD), cefoxitin (FOX), cephalothin (KF), tetracycline (TE), streptomycin (S), imipenem (IPM), nalidixic acid (NA), trimethoprim--sulfamethoxazole (SXT), and trimethoprim (W). *E. coli* ATCC^TM^ 25922 was included as a quality control strain. The strains were classified as susceptible or resistant to each antimicrobial agent. Strains giving *intermediate* values were considered susceptible. In addition, minimal inhibitory concentrations (MICs) of cefotaxime for donors and transconjugants combinations were determined using E-test strips (AB Biodisk, Solna, Sweden).

DETECTION OF RESISTANCE GENES BY MICROARRAY (GENE CHIP)
-------------------------------------------------------

A DNA microarray analysis (AMR-ve Genotyping Kit, Clondiag Chip Technologies, Jena, Germany) was performed with the donor strains to detect the genes encoding resistance to aminoglycosides, β-lactams, chloramphenicol, erythromycin, quinolone, sulphonamides, tetracycline, trimethoprim, and an integrase-encoding gene (*intI*).

PHYLOGENETIC CLASSIFICATION
---------------------------

Donor isolates that transferred cefotaxime resistance to *E. coli* 26R 793 were classified into the four main phylogenetic groups (A, B1, B2, and D) using a previously described triplex PCR-based protocol ([@B9]). Purified DNA served as a template. Thereafter, three specific primer sets (custom-synthesized by MWG-Biotech AG, Ebersberg, Germany) were used to identify the following markers; *chuA* (279 bp), *yjaA* (211 bp), and *tspE4* (152 bp; [@B9]).

MULTI-LOCUS SEQUENCE TYPING
---------------------------

Internal amplicons of seven housekeeping genes (*adk*, *fumC*, *gyrB*, *icdF*, *mdh*, *purA*, *recA*) from the donor strains were sequenced ([@B45]); alleles as well as sequence types (ST) were verified using the *E. coli* MLST website^[1](#fn01){ref-type="fn"}^

RESULTS
=======

PLASMID PROFILING
-----------------

Eighty-seven *E. coli* isolates were included in this study and low molecular weight (\<20-kb) plasmids could be identified by purification and conventional agarose gel electrophoresis. About half of the isolates (*n* = 46; 53%) carried several plasmids ranging in size from approximately 2- to 20-kb, and 41 isolates (47%) were devoid of small plasmids.

Thirty-two isolates from the original set of 87 were selected for further study, based on their diverse plasmid profiles and the corresponding ESBL genotypes, reported previously ([@B17], [@B18]). All were assessed for the presence of large plasmids (ranging in size from 30- to 600-kb) by S1 nuclease digestion followed by PFGE ([@B1]). S1 nuclease plasmid analysis revealed that all 32 contained detectable large plasmids; most possessed two plasmids (*n* = 13, 40.6%) and some (*n* = 9, 28.1%) had three plasmids. Heterogeneity among the profiles was a common feature noted, although most of the plasmid profiles were related among strains isolated from particular sources. Majority of the human isolates (*n* = 12, 86%) carried two or more large (≥20-kb) plasmids and a similar situation was noted for isolates cultured from the animal sources (*n* = 16, 89%; **Figure [1](#F1){ref-type="fig"}**).

![**A heat-map summary of the sources; a schematic showing the S1 nuclease plasmid profile; ESBL present/absent profiles; the resistance profile and the corresponding Inc plasmid type(s) for all 32 ESBL-positive *E. coli* previously reported from healthy food-producing animals and humans in Switzerland.** Black squares shown indicate a feature present in that isolate denoting its original source the ESBL marker(s) detected, its corresponding antimicrobial resistance profile and the Inc types detected. White squares denote features that are lacking in the corresponding bacterial isolate. Isolate numbers denotes by the grayed boxes on the left of the heat-map indicate those bacteria that contained self-transmissible ESBL-harboring plasmids (they are investigated further, as described in **Figure [2](#F2){ref-type="fig"}**). Antimicrobial compounds (it is known that many ESBL producers may appear susceptible or intermediate to certain oxyimino cephalosporins *in vitro*, if CLSI criteria are applied strictly, but do not respond to the respective therapies. Consequently, for clinical reporting these results have to be corrected to "resistant.") used are abbreviated as follows: AM, ampicillin; AMC, amoxicillin--clavulanic acid; CAZ, ceftazidime; CF, cephalothin; CPD, cefpodoxime; CIP, ciprofloxacin; CTX, cefotaxime; CXM, cefuroxime; FEP, cefepime; GM, gentamicin; S, streptomycin; SXT, trimethoprim-sulfamethoxazole; TE, tetracycline.](fmicb-04-00188-g001){#F1}

PBRT OF ISOLATES EXPRESSING AN ESBL-PHENOTYPE
---------------------------------------------

Eighteen plasmid replicons were detected by qualitative PBRT ([@B8]) among those 32 isolates carrying large (≥20-kb) plasmids. Replicon typing was identified 11 of 18 replicons. Interestingly, IncFIIA, IncFrep, IncHI2, IncL/M, IncW, IncT, or IncX types could not be detected, by PCR analysis in our collection. Nine Inc-types were identified among the isolates cultured from healthy humans. Of these, IncFIB (*n* = 9), IncFIA (*n* = 5), and IncK/B (*n* = 4) replicon types were the predominated types. Isolates recovered from poultry group had the highest number of IncI1 (*n* = 8) types. Three other replicon types were also detected in *E. coli* isolates cultured form poultry and these included IncFIB (*n* = 7), IncK/B (*n* = 4), and IncY (*n* = 3). When compared with the Inc-types identified in isolates cultured from humans, replicon types from the animal strains were less diverse. Several isolates were positive for more than one replicon type. The reason could be that they possessed multiple plasmids, or a single plasmid-encoded replication, or partitioning genes from more than one replicon family. A summary of these features along with the corresponding antimicrobial resistance profiles for all 32 isolates is shown as a heat-map in **Figure [1](#F1){ref-type="fig"}.**

CONJUGATION EXPERIMENTS WITH ESBL-PRODUCING ISOLATES
----------------------------------------------------

Each isolate of the 32 selected *E. coli*, elaborating an ESBL-phenotype, were tested for their ability to transfer the ESBL-resistant phenotype, by conjugation under laboratory conditions. Nine isolates transferred the cefotaxime resistance marker to a susceptible *E. coli* recipient with transfer rates ranging from 3.1 × 10^-2^ (in the case of L-2) to 5.7 × 10^-1^ (for C-49) transconjugants per donor cell. Transconjugants recovered were characterized as described below.

HORIZONTAL TRANSFER OF ANTIMICROBIAL RESISTANCE AND ASSOCIATED DETERMINANTS
---------------------------------------------------------------------------

With the exception of *E. coli* H-1519 cultured from a human and which contained two small plasmids (of 2- and 7-kb; data not shown), none of the other smaller (\<30-kb) plasmids could be transferred to the *E. coli* rifampicin-resistant recipient under laboratory conditions. Four isolates (H-2291, H-2332, C-59, and L-2) were identified wherein two large plasmids were transferred *via* conjugation and a further four (H-1038, C-23, C-49, and C-60) transferred a single large plasmid only (**Figure [2](#F2){ref-type="fig"}**).

![**A heat-map showing the comparison of ESBL-positive *E. coli* donors and the resultant transconjugants, characterized on the basis of their plasmid profiles; ESBL-markers identified by PCR; antimicrobial resistance profile; and plasmid replicon type(s).** The MIC for cefotaxime in each pairwise combination is also shown along with the fold increase in this value. (T) in the first column typifies the transconjugant. Black and white squares denote the presence and absence, respectively of a particular feature. The symbol "--" signifies no fold-change in the MIC for the transconjugant. Antimicrobial compounds are abbreviated as follows: AM, ampicillin; AMC, amoxicillin--clavulanic acid; C, chloramphenicol; CPD, cefpodoxime; CIP, ciprofloxacin; CTX, cefotaxime; KF, cephalothin; NA, nalidixic acid; S, streptomycin; SXT, trimethoprim-sulfamethoxazole; TE, tetracycline; W, trimethoprim.](fmicb-04-00188-g002){#F2}

Conjugation studies and plasmid profile analysis of all transconjugants showed that the nine isolates possessed 16 plasmids. Of these, 14 were large (\>30-kb) plasmids and the replicon types were also identified, by PCR. Six plasmids belonged to different donors and possessed IncI1 replicons. Three large plasmids contained IncFIB replicons and two contained IncN types. Single plasmids were typed as being members of the IncP or IncB/O replicon families (**Figure [2](#F2){ref-type="fig"}**).

Following conjugation the antimicrobial susceptibility of all nine transconjugants was determined by disk diffusion. In addition to cefotaxime resistance, resistance to several non-β-lactam-based antimicrobial compounds such as chloramphenicol, tetracycline, trimethoprim, and trimethoprim--sulfamethoxazole were also transferred to the recipient, suggesting that these markers are genetically linked. The MIC values recorded for all nine donors ranged from 96 to \>256 μg/ml by cefotaxime E-test. When these MIC values were measured for the transconjugants, all were recorded at 256 g/ml and in three cases there was between a 2- to 2.7-fold increase, in this value the MICs of transconjugants correspondingly were higher (\>256 μg/ml; **Figure [2](#F2){ref-type="fig"}**).

Twenty-eight antibiotic resistance-encoding genes were tested on commercial microarray in all nine donor strains. Only nine of these markers, including *aadA*, *cat*, *ctx*, *dfr*, *tem*, *tet*, *strA*, *strB*, and *sul* were detected. A CTX-encoding gene was detected in eight isolates, with an additional isolate positive for the TEM gene. These data were subsequently confirmed by PCR and the genes identified as *bla*~CTX-M-1~ and *bla*~TEM-52~, respectively. Five strains were positive for the *bla*~TEM-1~ gene. Six isolates were positive for the integrase-encoding gene (*intl*) associated with class 1 integrons. The genotypes of all nine donors and their corresponding transconjugants are summarized in **Figure [2](#F2){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**.

###### 

Summary of genotypic and phenotypic characteristics of nine ESBL--producing *E. coli* isolates cultured from healthy food--producing animals and humans in Switzerland.

  Isolate no.   Phylogenetic groups   Serotype   MLST                 Plasmid(s) (kb) isolated from transconjugants   Additional resistance determinants identified using a commercial microarray^[a](#fn03){ref-type="fn"}^
  ------------- --------------------- ---------- -------------------- ----------------------------------------------- --------------------------------------------------------------------------------------------------------
  H--1038       B1                    O8:H21     Unknown ST           140-                                            *aadA-strA-strB-cat-dfr-sul-tet-intl*
  H-1519        A                     O2:H48     ST10 complex         2-, 7-, 80-, 100-                               *--*
  H-2291        A                     O53:H18    ST1638               110-, 140-                                      *aadA-dfr-sul-tet-intl*
  H--2332       D                     O24:H26    ST57/ST350 complex   100-, 150-                                      *aadA-strA-strB-cat-dfr-sul-tet-intl*
  C--23         B1                    O3:Hnt     ST1389               100-                                            --
  C-49          B1                    Ont:H21    ST446 complex        110-                                            *aadA-strA-strB-dfr-sul-tet-intl*
  C-59          B1                    O86:H51    ST155 complex 1      110-, 150-                                      *aadA-cat-dfr-sul-tet-intl*
  C-60          B1                    O68:H21    ST3174 complex       110-                                            *aadA-strA-strB-dfr-sul-tet-intl*
  L-2           D                     Ont:H11    ST295                50-, 100-                                       *strB-cat-sul-tet*

Method used: Identi Bac Chip (AMR-ve Genotyping Kit, Version 05m); the symbol "--" signifies the fact that the bacterial isolate is negative for those genes included on the commercial microarray; "Ont" denotes an isolate whose serotype was non-typable.

GENOTYPING AND PHYLOGENETIC CLASSIFICATION OF NINE DONORS
---------------------------------------------------------

All donor isolates were sub-typed by MLST and eight STs and an unknown ST were identified (**Table [1](#T1){ref-type="table"}**). Genotypings identified were ST1389, ST604 (ST446 complex), ST155 (ST155 complex), ST3174, ST295, ST10 (ST10 complex), ST1638, ST57 (ST350 complex). The allele numbers of the unknown ST type were as follows: *adk* 6, *fumC* 4, *gyrB* 3, *icdF* 1, *mdh* 20, *purA* 8, *recA* 44.

The nine strains harboring self-transmissible plasmids could be assigned to phylogenetic groups A, B1, and D. Five isolates were assigned to group B1 and two assigned to group A. While two isolates were assigned to the D phylogenetic groups and non-isolate belonged to group B2 (**Table [1](#T1){ref-type="table"}**).

DISCUSSION
==========

By definition, plasmids do not carry genes essential for the growth of host cells under non-stressed conditions but most plasmids confer positively selectable phenotypes including antimicrobial resistance genes among others ([@B7]). Plasmids represent an important pool of adaptive and transferable genetic information and large plasmids (defined as being \>30-kb in size) are commonly being capable of transferring their genetic information in bacteria ([@B29]; [@B39]; [@B44]). Previously *E. coli* isolates were cultured from a number of healthy food-producing animals and humans in Switzerland and all expressed an ESBL-phenotype. In the collection of 32 isolates which were further studied, 82 megaplasmids were identified. Four plasmids had molecular sizes ranging from 200- to about 350-kb and a further 78 (95%) were large plasmids of sizes between 50- and 200-kb were observed. The approximate molecular sizes of plasmids were determined by comparing with the reference plasmids ([@B26]). At the outset, these data suggested that the ESBL markers may be mapped to larger sized plasmids (50- to 200-kb).

Currently, 27 Inc groups are recognized among the Enterobacteriaceae family ([@B7]). Particular plasmid incompatibility groups are more frequently encountered among *E. coli* and these play a major role in the dissemination of specific resistance genes. For instance, in Netherlands, genetically related IncI1 plasmids carrying the *bla*~CTX-M-1~ gene were identified in *E. coli* isolates from poultry meat samples and in infected individuals suggesting that transfer of these plasmids may have occurred among strains from food-producing animals and humans ([@B24]). CTX-M-1 was also identified on plasmids belonging to the IncN family in Europe among porcine ([@B28]), canine ([@B36]), and human *E. coli* isolates ([@B30]). In contrast, IncFII, IncA/C, IncL/M, IncN, and IncI1 plasmids carrying ESBL determinants are currently considered to be *epidemic resistance plasmids*, being detected in Enterobacteriaceae of different origin and sources ([@B7]). In the study reported here, PBRT typing identified 11 of 18 replicons (including IncA/C, IncB/O, IncFIA, IncFIB, IncFIC, IncHI1, IncP, IncK/B, IncI1, IncN, and IncY). IncFIB, IncK/B, and IncI1 were the more commonly identified replicon families in this study with 67% (*n* = 8) being IncI1 plasmids and which were isolated from the poultry samples. Moreover, conjugative transfer of plasmids belonging to incompatibility groups IncI1, IncFIB, and, less frequently, IncN, IncB/O, and IncP could be demonstrated under laboratory conditions, suggesting that the potential dissemination of these markers may exist in the wildlife (**Figure [2](#F2){ref-type="fig"}**). This observation is interesting given that plasmids of IncI (both IncI1 and IncI2) and IncF groups are commonly recovered from *E. coli* and *Salmonella* species cultured from both animals and humans, and they are also linked to a number of genes coding for ESBL-genotypes ([@B22]; [@B6]; [@B12]).

IncI1 plasmids are often associated with resistance to multiple antimicrobial compounds, particularly extended-spectrum cephalosporinases of both the CTX-M and CMY types ([@B20]; [@B27]). These have also been linked to TEM-52 enzymes. IncI1 plasmids producing TEM-52 have been identified in *E. coli* cultured from chicken and turkey meat in Denmark and the UK ([@B21]; [@B33]). Interestingly an IncI1 plasmid carrying *bla*~CTX-M-15~ and *bla*~TEM-1~ was associated with the recent 2011 outbreak of the *E. coli* O104:H4 in Germany^[2](#fn02){ref-type="fn"}^. Three conjugative IncI1 plasmids were identified among the *E. coli* isolates in this study. One such plasmid was from a healthy chicken isolate and contained a *bla*~TEM-52~ marker. Others may lead to the transfer of *bla*~CTX-M-1~ (**Figure [2](#F2){ref-type="fig"}**). These findings further support the suggestion that there may be prevalent plasmid types that are responsible for the dissemination of specific resistance genes in *E. coli* causing both community- and hospital-acquired infections ([@B38]; [@B20]; [@B30]).

IncF replicons (including FIA, FIB, and FIC) were the most frequently detected replicon types in the studied collection (45%). Interestingly, no IncFII type was identified. These data are in accordance with the previous reports ([@B22]; [@B27]). IncF replicons are widely distributed among *E. coli* and these plasmid types seem to be well adapted to this species. Three large potential conjugative plasmids (100- to 150-kb) of IncFIB replicon type were identified. This finding supports the view that IncF family plasmids play a major role in the dissemination of antibiotic resistance in Enterobacteriaceae, and some have been associated with specific genes conferring resistance to aminoglycosides, β-lactams, and quinolones ([@B20]; [@B27]). Plasmids of the IncP group are recognized as a significant antibiotic resistance marker reservoir due to their self-transmissibility and broad host range ([@B37]). Only a single possible conjugative IncP plasmid was identified among the transmissible plasmids studied. A similar situation was noted for the IncB/O type. This feature was interesting, given the fact that in previous studies IncP and IncB/O were the dominant Inc-types identified among transmissible plasmids characterized ([@B23]).

β-Lactamase-encoding (*bla*) genes have benefited from the various mechanisms available to promote HGT between bacteria, thereby ensuring the spread of these markers to new hosts. It is often included as component parts of multi-resistance plasmids commonly found in clinical isolates ([@B5]). Identification of the resistance genes together with an investigation of their potential for dissemination among bacteria of animal origin provides valuable insights into this important resistance gene pool ([@B29]). Use of extended-spectrum cephalosporins, in animal and human medicine can select for ESBL-genotypes. Dating back to the late 1990s, CTX-M enzymes are regarded as the predominant ESBL-types of animal origin as well as in human isolates in Europe ([@B25]). As TEM-1 is the most common plasmid-mediated β-lactamase identified in enteric Gram-negative bacilli, high rates of ampicillin-resistant, *bla*~TEM~-positive isolates are to be expected ([@B32]). In the current study, the *bla*~CTX-M-1~ gene was identified in eight transconjugants (including four from healthy humans, three from chickens, and one from a lamb; **Figure [2](#F2){ref-type="fig"}**). The *bla*~TEM-1~ gene was also identified in five transconjugants (four from healthy humans and one from a chicken sample; **Figure [2](#F2){ref-type="fig"}**). To our knowledge, neither *bla*~CTX-M-1~ nor *bla*~TEM-1~ associated with conjugative plasmids has been reported in healthy humans or food-producing animals in Switzerland.

In the laboratory, cefotaxime is used for optimum detection of *bla*~ESBL~-encoding isolates aiding in the identification of CTX-M carrying bacteria ([@B34]). In this study, cefotaxime resistance was observed to occur concomitantly with resistance to AMP/KF/CPD in eight transconjugants and this feature could be linked directly to the presence of *bla*~CTX-M-1~ (in eight of nine transconjugants), to *bla*~TEM-1~ (in five isolates), and to *bla*~TEM-52~ (in one isolate). However, only one --isolate showed resistance to amoxicillin--clavulanic acid (H-1519). As no evidence for mechanistic resistance, such as the expression of inhibitor-resistant TEM or SHV enzymes of the Bush--Jacoby groups 2be or 2ber ([@B5]) was detected (data not shown), this phenotype was most likely due to the hyper-expression of co-linear TEM-1 markers ([@B31]; [@B47]). Interestingly, the MICs of cefotaxime of three transconjugants \[C-23-(T); C-49-(T) and C-59-(T), **Figure [2](#F2){ref-type="fig"}**\] were between 2- and 2.7-fold higher than the corresponding donor strains. These increases indicated that an amplification of multiple copies of the ESBL gene or occurrence of a point mutation in one gene copy might increase specific activity of β-lactamase or downregulate its cell wall porins to increase resistance ([@B42]; [@B41]).

All nine transconjugants showed phenotypic resistance to more than one class of antimicrobial compound. One isolate \[H-1038-(T); **Figure [2](#F2){ref-type="fig"}**\] was found to be resistant to members of four different drug classes (aminoglycosides, chloramphenicol, sulfamethoxazole/trimethoprim, and tetracycline), and a further three \[H-2291-(T), H-2332-(T) and C-59-(T), **Figure [2](#F2){ref-type="fig"}**\] were resistant to three different antimicrobial compound classes (aminoglycosides, sulfamethoxazole/trimethoprim, and tetracycline or chloramphenicol). To our knowledge, this is the first evidence of this emerging multi-resistant clone with large conjugative plasmids from healthy humans and animals in Switzerland.

Recently, ESBL-producing *E. coli* ST131 and ST1722 were cultured from rivers and lakes ([@B47]) and ST61 was recovered from slaughterhouses ([@B14]) in Switzerland. Furthermore, ESBL-producing *E. coli* ST57 and ST371 were cultured from chickens in the UK, Germany, and Canada ([@B33]). Of the nine donor strains investigated in this study, the clonal lineages detected among healthy humans included phylogroup B1-O8:H21-unknown ST type, phylogroup A-O53:H18-ST1638, a pathogenic phylogroup D-O24:H26-ST57/ST350 complex, and phylogroup A-O2:H48-ST10 complex. Among the five animal isolates the lineages included phylogroup B1-O3:Hnt-ST1389, phylogroup B1-Ont:H21-ST446 complex, phylogroup B1-O68:H21-ST3174 complex, phylogroup B1-O86:H51-ST155 complex, and phylogroup D-Ont:H11-ST295 from a lamb source (**Table [1](#T1){ref-type="table"}**). Our study represents the first report of ESBL-producing *E. coli* of nine different ST types from animals and humans in Switzerland. Interestingly, these showed a distribution of plasmid replicon types similar to those reported previously in unselected *E. coli*, whereas in contrast the distribution of STs was markedly different ([@B13]; [@B33]). These finding may indicate the presence of systems affecting the incorporation and/or maintenance of antibiotic resistance genes not related to plasmid restriction ([@B2]).

Characterizing plasmids from bacteria of different origins may provide early insights into the epidemiology of important resistance markers, including ESBL-determinants. Few studies have provided clear evidence of a direct transmission of ESBL-producing *E. coli* isolates from food-producing animals and/or food to humans. Nonetheless, these data showed that MDR phenotypes, including resistance to newer generations of antimicrobial compounds, were transferable and in some cases were directly linked to large conjugative plasmids carrying multiple resistance genes. This situation could, in the future give rise to the co-selection, promoting the dissemination of ESBL-genotypes among bacteria of healthy food-producing animal and human origins alike.
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![**A heat-map summary of the original 87 ESBL-positive *E. coli* isolates previously reported from healthy food-producing animals and humans in Switzerland.** Black squares shown indicate a feature present in that isolate denoting its original source and the ESBL marker(s) detected; and white squares denote features that are lacking in the corresponding bacterial isolate. The approximate sizes of small plasmids are also showing in separate columns. The symbol "--" signifies no small (\<30-kb) plasmid in the corresponding strain. Isolate numbers denoted by the grayed boxes on the left of the heat-map indicate those bacteria that were selected for conjugation experiments and S1-nuclease-based PFGE studies (as described in **Figure [1](#F1){ref-type="fig"}**).](fmicb-04-00188-a001){#FA1}
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